Last reviewed · How we verify
Isoniazid with Ethambutol
Isoniazid and ethambutol are bactericidal and bacteriostatic agents that inhibit mycobacterial cell wall and metabolic synthesis, respectively, to treat tuberculosis infection.
Isoniazid and ethambutol are bactericidal and bacteriostatic agents that inhibit mycobacterial cell wall and metabolic synthesis, respectively, to treat tuberculosis infection. Used for Tuberculosis (pulmonary and extrapulmonary).
At a glance
| Generic name | Isoniazid with Ethambutol |
|---|---|
| Sponsor | Tuberculosis Research Centre, India |
| Drug class | Antituberculous agents |
| Target | InhA (isoniazid); arabinosyl transferases (ethambutol) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Isoniazid inhibits mycolic acid synthesis in the mycobacterial cell wall by targeting InhA (enoyl-ACP reductase), while ethambutol inhibits arabinosyl transferases involved in arabinogalactan synthesis. Together, they provide synergistic activity against Mycobacterium tuberculosis by disrupting essential cell wall components and metabolic pathways.
Approved indications
- Tuberculosis (pulmonary and extrapulmonary)
Common side effects
- Peripheral neuropathy
- Hepatotoxicity
- Optic neuritis
- Hyperuricemia
- Gastrointestinal disturbance
Key clinical trials
- Safety and Tolerability of Metformin in People With Tuberculosis (TB) and Human Immunodeficiency Virus (HIV) (PHASE2)
- Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis (PHASE2)
- AIPH-TB: AI-Optimised Pyrazinamide-Hydroxychloroquine vs Standard RIPE for Drug-Sensitive Pulmonary Tuberculosis - A Phase II RCT (PHASE2)
- Phase 2a Trial of Alpibectir Plus Ethionamide for Tuberculosis Meningitis (PHASE2)
- Digitally Facilitated, Integrated Community and Facility-Based Interventions: The HEART-TB Trial Protocol (NA)
- Asymptomatic TB With Innovative Modified Short-course Regimens (PHASE4)
- ATORvastatin in Pulmonary TUBerculosis: a POPulation PharmacoKinetics -PharmacoDynamics Sub-study (ATORTUB popPK-PD) (PHASE2)
- Phase 2 Trial to Evaluate the Safety and Tolerability and Early Bactericidal Activity of RESP30TB in Tuberculosis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Isoniazid with Ethambutol CI brief — competitive landscape report
- Isoniazid with Ethambutol updates RSS · CI watch RSS
- Tuberculosis Research Centre, India portfolio CI